Stephen Tyring, Angela Moore, Akimchi Morita, H Chih-Ho Hong, In-Ho Song, Jason Eccleston, Gweneth Levy, Mohamed-Eslam F Mohamed, Yuli Qian, Tianshuang Wu, Anqi Pan, Kinjal Hew, Kim A Papp
BACKGROUND: Dysregulated interleukin (IL)-17/IL-23 signaling contributes to psoriasis pathogenesis. Cedirogant is an inverse agonist of retinoic acid-related orphan receptor gamma thymus (RORγt), a key transcription factor responsible for IL-17 synthesis and a regulator of the T helper 17 cell lineage program. OBJECTIVE: To evaluate the efficacy and safety of cedirogant to treat moderate-to-severe psoriasis. METHODS: In this phase 2b, multicenter, double-blind, 16-week study (NCT05044234), adults aged 18-65 years were randomized 1:1:1:1 to once-daily oral cedirogant 75 mg, 150 mg, 375 mg, or placebo...
May 3, 2024: Clinical and Experimental Dermatology